SUPN - Supernus Pharmaceuticals GAAP EPS of $0.14 misses by $0.15 revenue of $170.05M beats by $5.82M
- Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q2 GAAP EPS of $0.14 misses by $0.15 .
- Revenue of $170.05M (+674.0% Y/Y) beats by $5.82M .
- Outlook 2022: Total revenues $640M - $680M. Consensus $674.55M.
- Operating earnings $20M - $40M
For further details see:
Supernus Pharmaceuticals GAAP EPS of $0.14 misses by $0.15, revenue of $170.05M beats by $5.82M